Also, systemic administration of AT-MSCs exerted neuroprotection by induction of a shift in the secretome of local glial cells toward a neuroprotective phenotype in the SOD mouse model of ALS. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.